MedTrace Logo

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

NCT05923515 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-06-28

No results posted yet for this study

Summary

A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Conditions

  • Malignant Pleural Effusion

Interventions

DRUG

JMKX000197

for injection

Sponsors & Collaborators

  • Zhejiang Hangyu Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Jianying Huang · Zhongnan Hospital of Wuhan University，No. 169, Donghu Road, Wuchang District, Wuhan, Hubei

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2025-04-30
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05923515 on ClinicalTrials.gov